The complaint filed against the NASDAQ-listed company alleges that Capricor disseminated false and misleading statements regarding its regulatory progress. Central to the dispute is the company's decision to modify its statistical analysis plan for Deramiocel. Legal filings assert that Capricor failed to secure FDA concurrence for these adjustments before resubmitting its Biologics License Application, rendering its public disclosures materially inaccurate throughout the specified class period.
Capricor Therapeutics Faces Class Action Over Deramiocel Disclosures
Investors who purchased Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, face a critical deadline today, September 28, to join a securities class action lawsuit. The litigation targets alleged violations of the Securities Exchange Act following the company’s handling of clinical data for its drug, Deramiocel.
The DJS Law Group, led by David J. Schwartz, is currently organizing the class and seeking potential lead plaintiffs. While the firm emphasizes its background in high-stakes corporate governance and securities litigation, participation in the lawsuit does not mandate a formal lead plaintiff appointment for shareholders seeking to recover losses. Investors interested in the action or seeking further information regarding their legal standing are encouraged to reach out to the firm’s Eastchester, New York office.
Comments (0)
No comments yet. Be the first!